Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-003 in treatment-naïve chronic HBV infection
NCT05542979Phase 1Completed
- Sponsor
- Huahui Health
- Start
- Aug 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing HH-003 Group with Placebo Group (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 57, Peak concentration at Day 113 and 3 more. Started Aug 2019; status: completed.
02
Drugs
Libevitug
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05542979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542979.